Meeting with BGI at the 2nd Bio-Expo, Wuhan, China
Innovation and optimal health were the themes of the second Bio-expo held June 30 to July 2 in Wuhan, the most populous city in central China nicknamed the “Optics Valley of China." BGI attracted much attention during the expo and summit on healthy China. Many visitors showed interest in BGI DNA sequencers, including BGISEQ-500 and BGISEQ-50, and their varied applications.
Wuhan has geographical advantages as a Chinese hub for the bio-industry. To further, the expo demonstrates opening of the Chinese supply-side in the biologics and health industry. Accordingly, the expo is a platform for BGI and other research institutes in the fields of biology, medicine, and the financial sector to discuss differing strategies, share practice and outcomes, as well as seek capital and cooperation. During the expo, BGI Chairman Wang Jian discussed the evolution of BGI, which became a large-scale clinical gene sequencing company in 2015. Globally, there are only two other companies in two nations that can compete with BGI. BGI’s advantages include large-scale production capacity, strong cost control and outstanding performance compared to its peers.
Through the development of gene sequencing technology BGI has committed to preventing epidemics and infectious diseases, eliminating birth defects, cancer, as well as cardiovascular disease, and is expanding public gene testing in several cities within China, with an aim of making such testing universal.